Finally, we want to draw attention to the fact that genotype 148Asp/Glu APEX which itself increases the risk of CRC (OR 2.588 (1.736–3.859); p < 0.0001), when considered along with any polymorphism of 689Ser/Arg ERCC4 (Ser/Ser, Ser/Arg, or Arg/Arg), will always show a greater risk than alone (OR, resp., 2.716 (1.293–5.704), p = 0.007, 2.963 (1.467–5.985), p = 0.002, and 2.643 (1.171–5.965), p = 0.018). This evidence concerns the gene ERCC4 and colorectal carcinoma.